Implications for multiple sclerosis in the era of the Affordable Care Act: an evolving treatment paradigm.
The treatment paradigm for multiple sclerosis (MS) continues to evolve as additional pharmacotherapeutic options become available. Furthermore, treatment individualization has become more feasible as new medications with distinct mechanisms of action and improved adverse event profiles have reached the market. As such, clinicians should familiarize themselves with the available treatment options, paying particular attention to their various advantages and disadvantages. In order to offer patients optimal MS therapy, it is crucial for clinicians to stay current with the changing landscape of multiple sclerosis. This article provides a review of the available pharmacotherapeutic options for treating MS, discusses the impact of adherence to therapy, and describes the importance of managing comorbidities often experienced by patients with MS.
Luigi
L
Brunetti
brunetti@pharmacy.rutgers.edu.
Samuel F
SF
Hunter
D004358:Drug Therapy / Q000639:trends*; D006801:Humans; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D058991:Patient Protection and Affordable Care Act; D010641:Phenotype; D017410:Practice Guidelines as Topic; D014481:United States